BridgeBio have substantially improved this course of an innovative therapy for ATTR-CM, employing the investigational drug. Preliminary patient data reveals promising outcomes for individuals suffering from a serious condition. The emphasis highlights the company’s dedication to treating unmet healthcare requirements in a heart disease field. At